(Press-News.org) SEATTLE – February 17, 2026 – Fred Hutch Cancer Center scientists reached a crucial milestone in blocking Epstein Barr virus (EBV), a pathogen estimated to infect 95% of the global population that is linked to multiple types of cancer, neurodegenerative diseases and other chronic health conditions.
Using mice with human antibody genes, the research team developed new genetically human monoclonal antibodies that prevent two key antigens on the surface of the virus from binding to and entering human immune cells. Published in Cell Reports Medicine, the study highlights one of the newly identified monoclonal antibodies that successfully blocked infection in mice with human immune systems when they were challenged with EBV.
“Finding human antibodies that block Epstein Barr virus from infecting our immune cells has been particularly challenging because, unlike other viruses, EBV finds a way to bind to nearly every one of our B cells,” explained Andrew McGuire, PhD, a biochemist and cellular biologist in the Vaccine and Infectious Disease Division at Fred Hutch. “We decided to use new technologies to try to fill this knowledge gap and we ended up taking a critical step toward blocking one of the world’s most common viruses.”
A new scientific approach yields answers to a puzzling challenge
A key challenge in the study was to pursue human monoclonal antibodies that could successfully halt EBV infection without triggering an anti-drug response to the antibodies themselves, a common response among patients treated with antibodies raised in other animals. The researchers targeted two antigens, gp350, which helps EBV bind to cell receptors, and gp42, which allows EBV to enter and infect human cells through a process called fusion. Using an innovative mouse model carrying human antibody genes, the effort yielded two monoclonal antibodies against gp350 and eight against gp42.
“Not only did we identify important antibodies against Epstein Barr virus, but we also validated an innovative a new approach for discovering protective antibodies against other pathogens,” noted Crystal Chhan, a pathobiology PhD student in the McGuire Lab. “As an early-career scientist, it was an exciting finding and has helped me appreciate how science often leads to unexpected discoveries.”
With help from Fred Hutch’s Antibody Tech Core, further analysis found sites of vulnerability that could be useful in future vaccine development. In the final step of the study, the research team discovered that one of the monoclonal antibodies against gp42 successfully prevented infection of EBV. Another monoclonal antibody against gp350 provided partial protection.
Hope for patients at the highest risk of Epstein Barr virus
More than 128,000 people in the U.S. undergo solid organ and bone marrow transplant annually. However, there are no specific therapies to prevent EBV from infecting or reactivating in patients undergoing immunosuppression for transplant procedures. Post-transplant lymphoproliferative disorders (PTLD) are an aggressive and sometimes life-threatening lymphoma that can develop after immune suppression and is most often caused by unchecked EBV infection.
“Post-transplant lymphoproliferative disorders (PTLD), most of which are EBV-associated lymphomas, are a frequent cause of morbidity and mortality after organ transplantation,” noted Rachel Bender Ignacio, MD, MPH, an associate professor and infectious disease physician at Fred Hutch and University of Washington School of Medicine. “Preventing EBV viremia has strong potential to reduce the incidence of PTLD and limit the need to reduce immunosuppression, thereby helping preserve graft function while improving overall patient outcomes. Effective prevention of EBV viremia remains a significant unmet need in transplant medicine.”
Transplant recipients may experience infection if their donor was exposed to EBV and passed on latent virus through the donor cells, or for transplant patients who already have had EBV infection, immunosuppression may cause latent virus in their bodies to replicate unchecked. Children undergoing immunosuppression for transplant could especially benefit from a specific therapy to prevent EBV, as a higher proportion of children have not yet been exposed to EBV.
The next mile
The scientists envision a future therapy in which an infusion of these monoclonal antibodies could prevent PTLD by blocking EBV infection and activation in the patient populations who face the highest risk of EBV-related complications.
Fred Hutch has filed for intellectual property rights covering monoclonal antibodies identified in the study, and McGuire and Chhan are working with scientific collaborators and an industry partner to advance a potential therapy for immunocompromised patients. A potential therapy could be tested for safety in healthy adult volunteers and, if acceptable, proceed to clinical trials in the relevant patient population.
“There’s momentum to advance our discovery to a therapy that would make a huge difference for patients undergoing transplant,” said McGuire. “After many years of searching for a viable way to protect against Epstein Barr virus, this is a significant stride for the scientific community and the people at the highest risk of complications from this virus.”
# # #
Media Contact:
media@fredhutch.org
206-667-2210
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center unites individualized care and advanced research to provide the latest cancer treatment options while accelerating discoveries that prevent, treat and cure cancer and infectious diseases worldwide.
Based in Seattle, Fred Hutch is an independent, nonprofit organization and the only National Cancer Institute-designated cancer center in Washington. We have earned a global reputation for our track record of discoveries in cancer, infectious disease and basic research, including important advances in bone marrow transplantation, immunotherapy, HIV/AIDS prevention and COVID-19 vaccines. Fred Hutch operates eight clinical care sites that provide medical oncology, infusion, radiation, proton therapy and related services. Fred Hutch also serves as UW Medicine’s cancer program.
END
In an early test of how AI can be used to decipher large amounts of health data, researchers at UC San Francisco and Wayne State University found that generative AI tools could perform orders of magnitude faster — and in some cases better than computer science teams that had spent months poring over the data.
Teams of scientists and scientists paired with AI were given the same task: predict preterm birth based on data from more than 1,000 pregnant women.
Even a junior research duo composed of a master’s student at UCSF, Reuben Sarwal, and a high school ...
About The Study: In this analysis of 6 pooled cohorts, higher levels of moderate to vigorous physical activity (MVPA) after a cancer diagnosis were associated with lower risk of cancer mortality among people previously diagnosed with 1 of 7 cancers not commonly studied for their association with MVPA. These findings suggest that it is important for health care professionals to promote physical activity for longevity and overall health among people living with and beyond cancer.
Corresponding Author: To contact the corresponding author, Erika Rees-Punia, PhD, email erika.rees-punia@cancer.org.
To ...
About The Study: This cohort study of patients with chronic kidney disease (CKD) suggests that a more advanced CKD stage was associated with increased incidence of cognitive impairment. These findings underscore CKD severity as a risk factor for cognitive decline across the CKD spectrum.
Corresponding Author: To contact the corresponding author, Tanika N. Kelly, PhD, MPH, email tkelly5@uic.edu,
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2025.59834)
Editor’s ...
PALM DESERT, Ca., February 17, 2026 — New research highlighting the growing potential of radiopharmaceutical therapies (RPT) to improve outcomes for people with cancer will be presented at the inaugural Multidisciplinary Radiopharmaceutical Therapy Symposium, taking place in Palm Desert, California, and online starting today. Studies at the meeting, sponsored by the American Society for Radiation Oncology (ASTRO), span established uses of RPT and early signals for new indications, while also addressing what clinics need in place to safely offer these treatments as they move into ...
PLYMOUTH MEETING, PA [February 17, 2026] — The National Comprehensive Cancer Network® (NCCN®) today published new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Pediatric Soft Tissue Sarcomas. This is the 7th NCCN Guidelines® for a pediatric cancer, expanding the overall library to cover 91 topics in cancer care. The guidelines present the latest evidence-based, expert consensus-driven recommendations for nearly every type of cancer plus prevention, screening, survivorship, and supportive care. NCCN Guidelines are updated at least once a year and help cancer care providers worldwide ...
Four New York University faculty have been awarded fellowships from the Alfred P. Sloan Foundation: Danique Jeurissen, an assistant professor of neural science, and Marvin Parasram, an assistant professor of chemistry, as well as Florian Schäfer and Joseph Tassarotti, assistant professors in NYU’s Courant Institute School of Mathematics, Computing, and Data Science.
“The Sloan Research Fellows are among the most promising early-career researchers in the US and Canada, already driving meaningful progress in their respective disciplines,” says Stacie Bloom, president and chief executive officer of the Alfred P. Sloan Foundation. “We look forward to seeing ...
The way we understand the movement of our own bodies plays an important role when learning physical skills, from sports to dancing. But a new study finds this phenomenon works very differently for people learning to use robotic prosthetic devices.
“When people first start walking with a prosthetic leg, they think their bodies are moving more awkwardly than they really are,” says Helen Huang, corresponding author of a paper on the work. “With practice, as their performance improves, people still do a poor job of assessing how their bodies move, but they are inaccurate in a very ...
What types of photos make people reach for their wallets? New Stanford University-led research suggests that brain activity can help forecast which wildlife images will inspire people to engage online and donate to conservation causes. The insights could help environmental organizations design more effective communications campaigns. The findings suggest that socioemotional features, such as visible faces or cues that encourage viewers to infer an animal’s mental state, played a key role in driving engagement.
The ...
New research shows that short periods of extreme heat and drought during flowering could become one of the biggest threats to global wheat production in the coming decades.
As the climate changes, farmers around the world are facing more frequent and intense weather extremes. While drought has long been seen as the main danger to wheat crops, this new study suggests that heatwaves at a key moment in the plant’s life cycle may soon pose an even greater risk.
Flowering: a critical moment:
Dr Mikhail Semenov, ...
Harlequin ichthyosis (HI) is a rare, severe genetic skin disorder caused by ABCA12 mutations, leading to defective lipid transport and loss of skin barrier function. Infants present with thick, armor-like plates, deep fissures, ectropion, and eclabium, with high risks of dehydration, infection, and respiratory failure. Historically fatal, survival has improved with neonatal intensive care and systemic retinoids. This review covers pathophysiology, clinical features, diagnosis, management, genetic counseling, and emerging gene-based therapies.
Introduction
HI is the most severe form of congenital ichthyosis. Newborns are encased in rigid hyperkeratotic ...
